(DVA) DaVita Inc. Company Overview

What does DaVita do?

DaVita Inc. is a kidney-care services company whose common stock trades on the NYSE under the ticker DVA. The company describes itself in its 2025 Form 10-K as a comprehensive kidney care provider focused on patients across the kidney-health journey, from chronic kidney disease management to dialysis treatment and transplant support. The core business is not selling a device or a drug; it is operating a large clinical service network that delivers life-sustaining treatments several times per week for patients whose kidneys have failed.

Why is dialysis a recurring-care business?

End-stage kidney disease is usually irreversible. Dialysis removes toxins, excess fluid and salt from the blood by artificial means, and many patients need regular therapy for the rest of their lives or until they receive a transplant. That creates a recurring service model: center staffing, medical director relationships, supplies, scheduling, payer billing and quality systems must be reliable every day. DaVita’s own company overview presents the same idea in mission terms: deliver holistic care through the kidney disease journey.

Where does DaVita operate?

The U.S. dialysis business is the center of the company’s economics. At FY2025 year-end DaVita operated in 46 states and the District of Columbia and contracted to provide inpatient dialysis in about 740 hospitals. Internationally, it served about 94,500 patients in 14 countries. The practical implication is that DaVita combines local clinical density with centralized billing, purchasing, compliance, technology and capital allocation.

How does DaVita make money, and which revenue stream matters most?

DaVita makes money primarily by receiving reimbursement for dialysis treatments and related kidney-care services. In FY2025, total revenue was $13.643B. U.S. dialysis generated $11.793B, or about 86% of consolidated revenue before intersegment eliminations. Other ancillary services, including international operations, U.S. integrated kidney care, clinical research, transplant software and venture activity, generated $1.922B. The scale is useful, but the key analytical question is payer mix: government programs cover most patients, while commercial plans represent a smaller share of patients but a much larger share of revenue.

Which payer groups fund the U.S. dialysis business?

In FY2025, government-based programs represented about 68% of U.S. dialysis patient service revenue and about 89% of U.S. patients. Medicare and Medicare Advantage alone represented 57% of U.S. dialysis patient service revenue; Medicaid and managed Medicaid represented 7%; other government programs represented 3%; and commercial plans, including hospital dialysis services, represented 32%. That mix explains why a modest change in commercial contracting, Medicare base rates or patient insurance status can matter more than the absolute number of treatments.

How do reimbursement and treatment volume drive dialysis economics?

Two variables dominate the U.S. dialysis model: number of treatments and average revenue per treatment. DaVita reported average patient service revenue per treatment of $409.56 for FY2025, up $18.24 from FY2024. It also disclosed that outpatient, home-based and hospital inpatient dialysis represented about 76%, 18% and 6% of U.S. dialysis revenue, respectively. For valuation work, this means the revenue line is not just volume multiplied by price; it is volume, modality mix, commercial mix, reimbursement policy, collections and service setting.

Why did DaVita become strategically important in kidney care?

DaVita’s importance comes from its position between patients, nephrologists, hospitals, payors and government reimbursement systems. The company’s stated mission is to be the provider, partner and employer of choice, and its public mission and values page frames “DaVita” as “giving life.” For analysis, the more useful point is that culture, clinical reliability and operational discipline are not soft accessories; they are part of running a labor-intensive, regulated, recurring-care network.

1. 2000
   The DaVita identity and mission-based operating culture replaced the older Total Renal Care story; the change still matters because staff retention and clinic execution are central to dialysis quality.
2. 2019
   DaVita completed the sale of its prior DaVita Medical Group business to Optum, sharpening the company around kidney care rather than broad physician-practice ownership.
3. 2024
   International operations expanded after consolidation of Asia-Pacific joint venture centers, increasing non-U.S. scale while keeping U.S. dialysis as the profit core.
4. 2025
   DaVita acquired dialysis operations in Brazil from Fresenius Medical Care affiliates for initial consideration of about $94.3M, adding to its international platform.
5. 2025
   Integrated Kidney Care reached profitability ahead of expectations according to the 2026 proxy letter, making value-based care more than a distant strategic narrative.
6. 2026
   The first-quarter update raised adjusted operating income and EPS guidance, reinforcing the current focus on treatment stability, reimbursement and labor productivity.

What changed after the 2019 DaVita Medical Group sale?

The 2019 Optum transaction removed a broader physician-services platform and left investors with a cleaner kidney-care company. That matters for students building a business model canvas: the key activities are no longer spread across general medical groups, but concentrated in dialysis center operations, hospital services, home dialysis, risk-based kidney care and international dialysis acquisitions. It also makes the current risk profile more focused: reimbursement, treatment volume, clinical staffing, payer contracting, regulation and debt service explain more than diversified healthcare exposure.

What does DaVita’s latest quarter show?

The freshest official reporting package is the quarter ended March 31, 2026. In the Q1 2026 earnings release, DaVita reported consolidated revenue of $3.416B, operating income of $482M, diluted EPS from continuing operations of $2.87, operating cash flow of $321M and free cash flow of $140M. The Q1 2026 Form 10-Q provides the filing-level detail behind the same performance.

What changed from Q1 2025?

Revenue rose because U.S. dialysis revenue per treatment improved and ancillary services grew. Total Q1 2026 revenue increased $192M from Q1 2025, while operating income increased $43M. Net income attributable to DaVita increased to $197.5M from $162.9M. The operating signal is positive, but it is not a volume boom: U.S. dialysis treatments were 7.030M, down slightly year over year, while average treatments per normalized day rose 0.4%.

What does the revenue trend look like?

How financially strong is DaVita?

DaVita is profitable and cash-generative, but it also carries a large debt load and a negative book equity position after years of repurchases. FY2025 operating cash flow was $1.887B and free cash flow was $1.024B. At March 31, 2026, cash and equivalents were $644M, short-term investments were $22M, total assets were $17.499B, long-term debt was $10.514B, and total DaVita shareholders’ equity deficit was $755M. That combination is common in leveraged buyback stories: the income statement and cash flow statement may look strong while the balance sheet remains interest-rate and refinancing sensitive.

How much cash converts into free cash flow?

What should investors infer from the debt profile?

DaVita refinanced major credit facilities in 2025, issued $1.0B of 6.75% senior notes due 2033, and purchased $4.75B of additional interest-rate cap notional exposure to reduce exposure to significant rate increases through 2029. The important point is not only the absolute leverage. It is the interaction among predictable treatment demand, regulated pricing, labor costs, debt expense and buybacks. A DCF model that assumes stable revenue growth but ignores interest costs, revolver usage and working-capital timing will miss the real capital-structure sensitivity.

Which kidney-care KPIs best explain DaVita’s performance?

For DaVita, the best KPIs are clinical-service operating metrics rather than simple store counts. A student should focus on treatment volume, average treatments per day, normalized treatment growth, revenue per treatment, patient care cost per treatment, payer mix, center footprint, DSO and capital spending. These metrics connect directly to revenue, margins, working capital and reinvestment.

How does modality mix shape the analysis?

Which external KPI matters most in 2026?

The CMS ESRD payment update is the clearest external KPI because it feeds directly into Medicare reimbursement. CMS finalized a CY2026 ESRD PPS base rate of $281.71 and projected a 2.2% increase in total payments to ESRD facilities compared with CY2025 in the official CY2026 ESRD PPS final rule fact sheet. For DaVita, that rate update does not eliminate commercial-payer or labor pressure, but it is a necessary anchor for the public-payor side of the model.

Who owns DaVita stock and why does governance matter?

DaVita is not a controlled company with dual-class shares, but its ownership profile is unusual because Berkshire Hathaway-related ownership is very large. The 2026 proxy statement lists Warren E. Buffett and Berkshire Hathaway Inc. as beneficially owning 30,100,585 shares, or 45.5% of DaVita common stock, as of March 31, 2026. BlackRock was listed at 3,994,011 shares, or 6.0%. All directors and executive officers as a group owned 1,271,564 shares, or 1.9%.

Why does Berkshire’s ownership change the investor profile?

A 45.5% holder does not automatically dictate day-to-day operations, but it changes the governance context. Repurchases reduce the share count and can increase the ownership percentage of a large holder unless that holder sells proportionally. DaVita’s annual and quarterly filings also disclose repurchases from Berkshire under a share repurchase agreement. For students, this is a clean example of how capital allocation and ownership structure interact: buybacks are not just EPS math; they alter voting concentration, liquidity, control perception and governance incentives.

What do executive incentives signal?

The proxy states that 92% of target CEO compensation and 83% of target compensation for other named executive officers was at risk, with performance share units tied to adjusted EPS and relative TSR. That design fits DaVita’s public-company story: management is evaluated on financial results and shareholder value, while the regulated healthcare context requires compliance, clinical quality and patient safety guardrails.

Who competes with DaVita, and what gives it an advantage?

DaVita’s largest named competitor in the 2025 filing is Fresenius Medical Care, which also manufactures supplies and equipment as well as operates dialysis centers. DaVita also competes with large and mid-sized dialysis providers, private-equity-backed kidney care providers, individual nephrologists, former medical directors, hospitals and non-traditional entrants in integrated kidney care. The competitive field is therefore broader than a simple “clinic versus clinic” map.

What is the moat?

The moat is not a patent, a consumer brand or a network effect in the software sense. It is a combination of scale, local clinic density, medical director relationships, payer contracting, purchasing, compliance infrastructure, clinical quality systems and operational know-how. Medicare-certified centers require medical director agreements, qualified clinical staff and regulatory compliance. Patients and physicians can choose among providers, so DaVita must maintain referral relationships and service reliability rather than assume locked-in demand.

Where can competition pressure the model?

Competition can pressure DaVita through patient acquisition, medical director relationships, hospital contracts, skilled clinical labor, acquisition targets and integrated-care partnerships. Non-traditional providers may also compete in pre-dialysis care or technology-enabled kidney management. For MBA analysis, rivalry is moderate to high, buyer power is material because payors negotiate and regulate reimbursement, and supplier power matters because dialysis uses specialized equipment, pharmaceuticals, consumables and skilled labor.

What opportunities and risks could change DaVita’s outlook?

DaVita’s opportunity set is not about explosive unit growth. It is about improving revenue per treatment, growing home dialysis, expanding integrated kidney care, executing international acquisitions, improving labor productivity, reducing avoidable hospitalizations and using cash flow effectively. The biggest risks come from the same system: reimbursement, payer mix, staffing, regulation, supplier costs, technology shifts, cybersecurity, treatment alternatives and debt service.

Which risks are most company-specific?

The most company-specific risk is payer mix. DaVita treats a large share of government-program patients, but commercial revenue remains disproportionately important to profitability. A second risk is clinical labor. Dialysis is labor intensive, and competition for nurses and skilled clinical personnel can limit expansion or raise costs. A third is regulatory complexity: certificate-of-need rules, Medicare certification, waste disposal, OSHA requirements, antitrust oversight, information blocking, cybersecurity and privacy rules all sit inside the operating model.

Why does DaVita matter for valuation?

DaVita is a useful DCF case because the company combines recurring healthcare demand with regulated pricing, labor intensity, material debt and aggressive buybacks. The main value drivers are not speculative product launches. They are treatment growth, reimbursement, payer mix, cost per treatment, free cash flow conversion, debt expense, share count and terminal risk from new therapies or payment reform.

What should a DCF model sensitize?

A DCF model should sensitize revenue per treatment, patient care cost per treatment, normalized treatment growth, commercial mix, effective tax rate, maintenance capex, development capex, debt refinancing rates and share repurchase assumptions. DaVita’s financial reports page is useful because it lets a researcher compare multiple years of annual reports and quarterly packages instead of relying on one isolated data point. The SEC filings page is equally important for updates to debt, risk factors, ownership and capital allocation.

What is the key takeaway from DaVita analysis?

DaVita is important because it operates one of the largest kidney-care service networks in a recurring, medically necessary market. The company’s story is supported by scale, clinical infrastructure, a large U.S. dialysis footprint, payer relationships, free cash flow generation and a capital allocation pattern that has materially reduced shares outstanding. The story could weaken if commercial mix deteriorates, labor and supply costs outrun reimbursement, treatment volume stalls, new therapies slow ESKD progression faster than expected, or debt expense absorbs too much cash flow.